中华预防医学杂志
中華預防醫學雜誌
중화예방의학잡지
CHINESE JOURNAL OF
2009年
7期
615-618
,共4页
张佩如%祝小平%周良君%刘友全%凡娅%陈果%陈志%刘颜%孙宏英%吴建林
張珮如%祝小平%週良君%劉友全%凡婭%陳果%陳誌%劉顏%孫宏英%吳建林
장패여%축소평%주량군%류우전%범아%진과%진지%류안%손굉영%오건림
流感疫苗%安全%评价研究
流感疫苗%安全%評價研究
류감역묘%안전%평개연구
Influenza vaccines%Safety%Evaluation studies
目的 评价国产流行性感冒(简称流感)病毒裂解疫苗的安全性和免疫效果.方法 选择6岁~、16岁~和>60岁3个年龄段人群共606名,每个年龄段人群按数字表法随机分入试验组(共213名)、对照组1(共195名)和对照组2(共198名),分别接种国产流感疫苗和2种进口流感疫苗,比较三组人群接种后副反应发牛率、抗体阳转率、保护率及几何平均滴度(GMT)增长倍数的差异.率的比较采用X2检验,几何平均滴度(GMT)增长倍数采用方差分析,P<0.05为差异有统计学意义.结果 试验组、对照组1、对照组2副反应发生率分别为3.76%(8/213)、4.10%(8/195)和3.54%(7/198),差异无统计学意义(X2=0.87,P=0.93).3个组H1N1、H3N2和B(亚)型血凝抑制(H1)抗体总阳转率分别为89.2%(190/213)、63.4%(135/213)、86.4%(184/213),88.7%(173/195)、61.5%(120/195)、87.2%(170/195),87.9%(174/198)、61.6%(122/198)、84.8%(168/198),各(亚)型抗体总阳转率差异无统计学意义(X2H1N1=0.94,PH1N1=0.63;X2H1N2=0.94,PH3N2=0.63;X2B=0.75,PB=0.69);3个组H1N1、H3N2及B型H1抗体平均增长倍数分别为10.7、7.3、8.4倍,10.5、6.3、8.3倍,10.2、7.1、8.8倍,各(亚)型H1抗体GMT增长倍数差异无统计学意义(FH1N1=0.35,PH1N1=0.70;FH3N2=2.22,PH3N2=0.11;FB=1.51,PB=0.35);3个组H1N1、H3N2及B型H1抗体保护率分别为100%(213/213)、70.0%(149/213)、95.3%(203/213),100%(195/195)、66.7%(130/195)、97.9%(191/195),99.5%(197/198)、66.2%(131/198)、96.5%(191/198),各(亚)型抗体保护率差异无统计学意义(X2H1N1=2.04,PH1N1=0.36;X2H3N2=0.74,PH3N2=0.69;X2B=0.42,PB=0.82).结论 国产裂解流感疫苗具有良好的安全性和免疫效果,可用于群体性接种.
目的 評價國產流行性感冒(簡稱流感)病毒裂解疫苗的安全性和免疫效果.方法 選擇6歲~、16歲~和>60歲3箇年齡段人群共606名,每箇年齡段人群按數字錶法隨機分入試驗組(共213名)、對照組1(共195名)和對照組2(共198名),分彆接種國產流感疫苗和2種進口流感疫苗,比較三組人群接種後副反應髮牛率、抗體暘轉率、保護率及幾何平均滴度(GMT)增長倍數的差異.率的比較採用X2檢驗,幾何平均滴度(GMT)增長倍數採用方差分析,P<0.05為差異有統計學意義.結果 試驗組、對照組1、對照組2副反應髮生率分彆為3.76%(8/213)、4.10%(8/195)和3.54%(7/198),差異無統計學意義(X2=0.87,P=0.93).3箇組H1N1、H3N2和B(亞)型血凝抑製(H1)抗體總暘轉率分彆為89.2%(190/213)、63.4%(135/213)、86.4%(184/213),88.7%(173/195)、61.5%(120/195)、87.2%(170/195),87.9%(174/198)、61.6%(122/198)、84.8%(168/198),各(亞)型抗體總暘轉率差異無統計學意義(X2H1N1=0.94,PH1N1=0.63;X2H1N2=0.94,PH3N2=0.63;X2B=0.75,PB=0.69);3箇組H1N1、H3N2及B型H1抗體平均增長倍數分彆為10.7、7.3、8.4倍,10.5、6.3、8.3倍,10.2、7.1、8.8倍,各(亞)型H1抗體GMT增長倍數差異無統計學意義(FH1N1=0.35,PH1N1=0.70;FH3N2=2.22,PH3N2=0.11;FB=1.51,PB=0.35);3箇組H1N1、H3N2及B型H1抗體保護率分彆為100%(213/213)、70.0%(149/213)、95.3%(203/213),100%(195/195)、66.7%(130/195)、97.9%(191/195),99.5%(197/198)、66.2%(131/198)、96.5%(191/198),各(亞)型抗體保護率差異無統計學意義(X2H1N1=2.04,PH1N1=0.36;X2H3N2=0.74,PH3N2=0.69;X2B=0.42,PB=0.82).結論 國產裂解流感疫苗具有良好的安全性和免疫效果,可用于群體性接種.
목적 평개국산류행성감모(간칭류감)병독렬해역묘적안전성화면역효과.방법 선택6세~、16세~화>60세3개년령단인군공606명,매개년령단인군안수자표법수궤분입시험조(공213명)、대조조1(공195명)화대조조2(공198명),분별접충국산류감역묘화2충진구류감역묘,비교삼조인군접충후부반응발우솔、항체양전솔、보호솔급궤하평균적도(GMT)증장배수적차이.솔적비교채용X2검험,궤하평균적도(GMT)증장배수채용방차분석,P<0.05위차이유통계학의의.결과 시험조、대조조1、대조조2부반응발생솔분별위3.76%(8/213)、4.10%(8/195)화3.54%(7/198),차이무통계학의의(X2=0.87,P=0.93).3개조H1N1、H3N2화B(아)형혈응억제(H1)항체총양전솔분별위89.2%(190/213)、63.4%(135/213)、86.4%(184/213),88.7%(173/195)、61.5%(120/195)、87.2%(170/195),87.9%(174/198)、61.6%(122/198)、84.8%(168/198),각(아)형항체총양전솔차이무통계학의의(X2H1N1=0.94,PH1N1=0.63;X2H1N2=0.94,PH3N2=0.63;X2B=0.75,PB=0.69);3개조H1N1、H3N2급B형H1항체평균증장배수분별위10.7、7.3、8.4배,10.5、6.3、8.3배,10.2、7.1、8.8배,각(아)형H1항체GMT증장배수차이무통계학의의(FH1N1=0.35,PH1N1=0.70;FH3N2=2.22,PH3N2=0.11;FB=1.51,PB=0.35);3개조H1N1、H3N2급B형H1항체보호솔분별위100%(213/213)、70.0%(149/213)、95.3%(203/213),100%(195/195)、66.7%(130/195)、97.9%(191/195),99.5%(197/198)、66.2%(131/198)、96.5%(191/198),각(아)형항체보호솔차이무통계학의의(X2H1N1=2.04,PH1N1=0.36;X2H3N2=0.74,PH3N2=0.69;X2B=0.42,PB=0.82).결론 국산렬해류감역묘구유량호적안전성화면역효과,가용우군체성접충.
Objective To evaluate the safety and immunological effect of domestic split influenza virus vaccine. Methods All 606 subjects were divided into three groups by under 6, 16-60 and above 60 years old. Each age group was divided as study group(n=213) ,control group 1 (n=195) and control group 2(n=198) by Table of Random Number,one domestic vaccine and two imported vaccines were respectively inoculated in three group people. The differences of clinical side effect rate, antibody positive rate, protective rate and geometric mean titer (GMT) of these three vaccines were compared by using the statistical software with statistical significance of P<0. 05. Results The side effect rate of study group, control group 1 and control group 2 was 3.76% (8/213) ,4. 10% (8/195) ,and 3. 54% (7/198) ,respectively without statistical significance(X2=0. 87 ,P=0. 93). The positive seroconversion rates of HB1N1, H3N2 and B in these three groups were respectively 89. 2 % (190/213), 63.4% (135/213), 86. 4% (184/213), 88. 7 % (173/195), 61.5% (120/195), 87. 2% (170/195), 87.9% (174/198), 61.6% (122/198) and 84. 8% (168/198). There were no statistical significance in the total positive seroconversion rate of each antibody type(X2H1N1=0. 94, PH1N1=0. 63 ; X2H3N2=0. 94, PH3N2=0. 63 ; X2B=0. 75, PB=0. 69). The average growth multiple of H1 N1, H3N2 and B in these three groups were 10. 7,7.3,8.4,10. 5,6. 3,8. 3,10. 2,7. 1,8. 8 times. There were no statistical significances in the GMT growth multiple of each antibody type (FH1N1=0. 35, PH1N1=0. 70 ;FH3N2=2. 22,PH3N2=0. 11 ;FB=1.51 ,PB=0. 35). The antibody protective rates of H1N1 ,H3N2 and B were 100% (213/213) ,70. 0% (149/213) ,95.3% (203/213), 100% (195/195) ,66. 7% (130/195),97.9% (191/195) ,99. 5% (197/198), 66. 2% (131/198), 96. 5% (191/198) respectively. There was no statistical difference among the three vaccines(X2H1N1=2. 04,PH1N1=0. 36;X2H3N2=0. 74,PXH3N2=0. 69;X2B=0. 42, PB=0. 82). Conclusion The domestic influenza split vaccine might be suitable for colony vaccination for its having clinical safety and immunological effect.